Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Retained Earnings (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Retained Earnings for 2 consecutive years, with $8000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 77.14% to $8000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8000.0 through Dec 2025, down 77.14% year-over-year, with the annual reading at $8000.0 for FY2025, 77.14% down from the prior year.
  • Retained Earnings hit $8000.0 in Q4 2025 for Prelude Therapeutics, up from -$666.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $35000.0 in Q4 2024 to a low of -$666.6 million in Q3 2025.